Visibility of prostate cancer on transrectal ultrasound during fusion with multiparametric magnetic resonance imaging for biopsy.
To determine transrectal ultrasound (TRUS) visibility of magnetic resonance (MR) lesions. Data from 34 patients with 56 MR lesions and prostatectomy were used. Five observers localized and determined TRUS visibility during retrospective fusion. Visibility was correlated to Prostate Imaging-Reporting and Data System (PIRADS) and Gleason scores. TRUS visibility occurred in 43% of all MR lesions and in 62% of PIRADS 5 lesions. Visible lesions had a significantly lower localization variability. On prostatectomy, 58% of the TRUS-visible lesions had a Gleason 4 or 5 component. Almost half of the MR lesions were visible on TRUS. TRUS-visible lesions were more aggressive than TRUS-invisible lesions.